Menu
Share this

PPD Recognized for Leadership in Clinical Research

25 May 2017

RSS

WILMINGTON, N.C., (May 25, 2017) – Pharmaceutical Product Development, LLC (PPD) today announced it has been recognized for excellence in clinical research by pharmaceutical and biotechnology executives surveyed for Life Science Leader magazine’s 2017 CRO Leadership Awards.

PPD earned high honors in all of the five distinct categories: capabilities, compatibility, expertise, quality and reliability. The results are based on survey responses from biopharmaceutical industry leaders responsible for making or influencing decisions to collaborate with contract research organizations (CROs) on clinical development programs.

PPD’s comprehensive offerings range from integrated early development through post-market services and PPD® Laboratories, offering the most comprehensive lab services available in the industry.

“PPD is committed to accelerating the generation of evidence necessary for our customers to bring life-changing therapies to society,” said David Simmons, chairman and CEO of PPD. “Pharmaceutical and biotechnology clients can rely on our expertise and tailored, quality-first services across Phase I-IV and post-approval research, with integrated and comprehensive laboratory services and industry leadership in site and patient relationships. Our strategically expanded service offerings help ensure our clients’ evolving needs are met with precision and high quality across the drug development continuum.”

The survey for the 2017 CRO Leadership Awards, which encompassed 27 performance metrics, was conducted by Industry Standard Research, a full-service pharmaceutical market research firm, to help Life Science Leader assess the performance of CROs.

About PPD

PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 47 countries and more than 19,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development to deliver life-changing therapies that improve health.

PPD Contacts
Media:
Elizabeth Humphrey
+1 910 558 6096
elizabeth.humphrey@ppdi.com

Investors:
Nate Speicher
+1 910 558 6783
nate.speicher@ppdi.com

Forward-looking Statement

Any statements made in this news release that are not statements of historical fact, including statements about the honors and accolades PPD receives, are forward-looking statements that involve a number of risks and uncertainties. These statements often include words such as “anticipate,” “expect,” “suggests,” “plan,” “believe,” “intend,” “estimates,” “targets,” “projects,” “should,” “could,” “would,” “may,” “might,” “will,” “forecast” and other similar expressions. The forward-looking statements contained in this news release are subject to and involve risks, uncertainties and assumptions, and therefore you should not place undue reliance on them. Although PPD believes these forward-looking statements are based on reasonable assumptions at the time they are made, many factors are beyond PPD’s ability to control or predict and could affect the outcome of the subject matter of this news release and our actual financial results, and therefore the outcome and results might differ materially from those expressed in the forward-looking statements.

Additional factors that might materially affect the forward-looking statements include, but are not limited to: the competitive nature of the drug development services industry; changes in trends in the biopharmaceutical industry; our ability to recruit, retain and motivate key personnel; rapid technological changes that make our services less competitive or obsolete; the impacts of political, economic and/or regulatory changes on the health care industry; the fact that our backlog may not accurately predict or convert into service revenue; the termination, delay or change in scope of our contracts; industry, customer or therapeutic concentration; the pricing of and cost management of customer contracts; information and communication systems failures; contractual failures; regulatory and ethical standards failures; our ability to attract investigators and enroll patients in clinical trials; violations of laws governing privacy, conduct of clinical trials and/or other pharmaceutical research; competition between existing and potential customers; management of business restructurings and acquisitions; risk relating to the performance of drug development services and our insurance coverages, if any, for such risks; U.S. or international economic, currency, political and other risks; changes in existing or interpretations of tax laws; factors impacting the value of our goodwill and intangible assets; and other factors.

PPD assumes no obligation and expressly disclaims any duty to revise or update any forward-looking statements, or make any new forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law. PPD is not responsible for updating the information contained in this news release beyond the published date, or for changes made to this news release by wire services or internet service providers or any other party.
###

Contact Us

Media Contacts:

Randy Buckwalter Senior Manager, Corporate Communications
PPD
Tel: +1 919 456 4425

Elizabeth Humphrey Corporate Communications Manager
PPD
Tel: +1 910 558 6096

Contact Legal Notices Modern Slavery Transparency Statement Privacy Policy

© 2017 Pharmaceutical Product Development, LLC. All rights reserved.